Hengrui Medicine: Subsidiary drug SHR-3079 injection approved to conduct clinical trials.

Hengrui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-3079 injection, and will soon start clinical trials. The drug is an innovative anti-tumor drug independently developed by the company, intended for the treatment of B-cell non-Hodgkin's lymphoma, with no similar drugs approved for market domestically or internationally. As of now, the total research and development investment for the project is approximately 23.4 million yuan. The drug development and approval process is long and complex, with uncertainties.